Editing
AUA: Upper Tract Urothelial Carcinoma (2023)
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== History and Physical exam === * <span style="color:#ff0000">'''History'''</span> **<span style="color:#ff0000">'''Personal and family history to identify known hereditary risk factors for familial diseases associated with Lynch Syndrome'''</span> *** '''If positive, referral for genetic counseling should be offered.''' ****Patients with Lynch Syndrome undergo routine screening due to increased life-long risk for developing associated malignancies, often occurring before 50 years of age *** '''<span style="color:#ff0000">Lynch syndrome</span>''' ****Familial, autosomal-dominant multi-organ cancer syndrome ****'''Due to an inherited germline mutation in a group of DNA damage response genes responsible mismatch repair (MMR),''' specifically MLH1, MSH2, MSH6, PMS2, or EPCAM *****Alterations affecting the normal function of these genes results in an accumulation of DNA errors and increases the potential for cancer development **** '''Accounts β7-20% of UTUC cases in the U.S''' *****Lynch syndrome may increase the possibility of contralateral upper tract involvement, which is an important potential clinical consideration when developing a treatment plan. ****'''<span style="color:#ff0000">Associated cancers (11):</span>''' ****#'''<span style="color:#ff0000">Colorectal (20-80%)</span>''' ****#'''<span style="color:#ff0000">Urothelial (1-18%)</span>''' ****#'''<span style="color:#ff0000">Gastric cancers (1-13%)</span>''' ****#'''<span style="color:#ff0000">Endometrial (15-60%) in females</span>''' ****#'''<span style="color:#ff0000">Ovarian cancer (1-38%) in females</span>''' ****#'''<span style="color:#ff0000">Biliary</span>''' ****#'''<span style="color:#ff0000">Small bowel</span>''' ****#'''<span style="color:#ff0000">Pancreatic</span>''' ****#'''<span style="color:#ff0000">Prostate</span>''' ****#'''<span style="color:#ff0000">Skin</span>''' ****#*Sebaceous adenoma, sebaceous epithelioma, sebaceous adenocarcinoma, keratoacanthoma, and squamous cell carcinoma[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423888/] ****#'''<span style="color:#ff0000">Brain</span>'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information